• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

House passes “right to try” bill allowing use of experimental drugs for terminally ill patients

March 22, 2018 By Fink Densford

capitol hill

The US House of Representatives yesterday passed a bill aiming to expand the “right to try” experimental drugs, sending the bill, which is backed by President Trump, to the Senate.

The bill would allow terminally ill patients access to investigational drugs drugs that haven’t been approved by the FDA, according to a report from The Hill. Patients would be able to request drugs as long as those drugs had been through initial clinical trials and were under consideration by the FDA.

The bill was passed mainly along party lines by Republicans, with only two opposed to it, while 35 Democrats also supported the bill, according to the report.

Supporters of the bill claimed that it was necessary, and urged the Senate to quickly pass the legislation. The Senate had previously voted on its own version of the bill last August, passing it by unanimous consent, according to The Hill.

“Right to try needs to become the law of the land. It passed the Senate unanimously last summer, and I’m disappointed the House didn’t pass that bill and send it to the president for his signature. Nonetheless, I plan to ask my colleagues to pass right to try again immediately. Terminally Ill patients and their families have waited long enough,” Sen. Ron Johnson (R-Wis.), who supported the senate bill, said, according to the report.

Democrats and a number of patient advocacy groups voiced concerns about the bill, stemming mainly from patent safety issues.

“By allowing patients access to investigational treatments that have only completed a phase 1 clinical trial, patients will be exposed to treatments with no or relatively little data that they are actually effective,” Rep. Frank Pallone Jr. (D-N.J.), the top democrat on the House Energy and Commerce Committee said, according to The Hill. “These extremely small trials only examine the safety and toxicity of a drug and do not determine the effectiveness or potential side effects.”

Filed Under: Featured, Legal News, Pharmaceuticals Tagged With: U.S. House of Representatives

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS